tert-Butyl (2R,4S)-2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate, 98%, 1g

o-Anisidine , >=98%, for synthesis, 1 L, glass packaging

6-Bromo-7-hydroxy-4-(hydroxymethyl)coumarin>98.0%(T)1g

3-Methyl-quinoxaline-2-carboxylic acid, 95.0%, 1g

2,5-Dibromophenylboronic acid, 95.0%, 5g

1-(Piperidin-4-yl)-3-p-tolylurea hydrochloride, 95.0%, 1g

Trimethoxyphenylsilane>98.0%(GC)25mL

((2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 4-methylbenzenesulfonate, 97%, 1g

(2S,3R)-5-bromo-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)-2,3-dihydro-1-benzofuran, 95+%, 250mg

2-(tert-Butyl)-4,6-dichloropyrimidine, 97%, 10g

Ethyl S-4-chloro-3-hydroxybutyrate, 95.0%, 25g

(R,R'')-2,2''-Bis(diphenylphosphino)-1,1''-biferrocene>98.0%(T)500mg

6-Bromo-2-chloro-3-methylquinoline, 98%, 250mg